Nova Patents
AT352300T

Formulations of alpha adrenergic receptor antagonists and their uses

Abstract

This record has no abstract on file.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

36 members in 13 offices

This recordMember, by publication datePriority claim3 more offices are in the list below

Priority claims8

Priority claims
DocumentOfficeKindDate
20380000United States of AmericaP
20380000United States of AmericaP
23585500United States of AmericaP
23585500United States of AmericaP
203800P–––
235855P–––
US20000203800P–––
US20000235855P–––

Members36

Family members, oldest first
DocumentOfficeKind
CA2408417A1CanadaA1
WO0185171A1World Intellectual Property Organization (WIPO)A1
AU5984801AAustraliaA
US2001056125A1United States of AmericaA1
US6432401B2United States of AmericaB2
US2002183356A1United States of AmericaA1
US2002183396A1United States of AmericaA1
EP1280531A1European Patent Office (EPO)A1
JP2003532678AJapanA
ZA200209811BSouth AfricaB
US2004063747A1United States of AmericaA1
US6764678B2United States of AmericaB2
US2004198816A1United States of AmericaA1
NZ522930ANew ZealandA
US6872390B2United States of AmericaB2
EP1280531A4European Patent Office (EPO)A4
US2005165097A1United States of AmericaA1
US2005165098A1United States of AmericaA1
AU2001259848B2AustraliaB2
AU2005211689A1AustraliaA1
JP2006225400AJapanA
EP1280531B1European Patent Office (EPO)B1
AT352300TThis recordAustriaT
ATE352300T1AustriaT1
PT1280531EPortugalE
EP1762236A2European Patent Office (EPO)A2
DE60126265D1GermanyD1
DK1280531T3DenmarkT3
US7261889B2United States of AmericaB2
ES2281418T3SpainT3
DE60126265T2GermanyT2
EP1762236A3European Patent Office (EPO)A3
AU2005211689B2AustraliaB2
US2009076023A1United States of AmericaA1
CA2408417CCanadaC
EP1762236B1European Patent Office (EPO)B1